Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH505 mRNA-LNP HIV-1 vaccine
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
CH505 mRNA-LNP HIV-1 vaccine is an investigational mRNA-based vaccine regimen designed to prevent HIV-1 infection. Developed by the Duke Human Vaccine Institute (DHVI) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Pennsylvania, the vaccine utilizes lipid nanoparticles (LNPs) to deliver nucleoside-modified messenger RNA encoding transmembrane-stabilized gp160 envelope (Env) trimers derived from the clade C CH505 transmitted-founder (TF) strain. The vaccine regimen, evaluated in the Phase 1 HVTN 312 clinical trial, employs a sequential priming and boosting strategy (using CH505M5 N197D mRNA-gp160 followed by CH505 TF mRNA-gp160 and CH505 w24 mRNA-gp160) to target and expand unmutated common ancestors (UCAs) of the CH235 lineage, guiding B-cell maturation toward the development of CD4-binding site (CD4bs) broadly neutralizing antibodies (bnAbs).
- Other names
- CH505 gp160 mRNA-LNPCH-505 gp160 mRNA-LNPCH 505 gp160 mRNA-LNPCH505 mRNA-LNPCH-505 mRNA-LNPCH 505 mRNA-LNPHVTN 312 vaccineHVTN312 vaccineHVTN-312 vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on CH505 mRNA-LNP HIV-1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH505 mRNA-LNP HIV-1 vaccine.